Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the Chinese medicine sector [6]. Core Insights - The Chinese medicine sector saw a 1.08% increase last week, with the overall pharmaceutical sector experiencing a general upward trend [2]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.86X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.31X, also showing a minor rise [3]. - The market for Chinese medicinal materials is currently in a low season, with a slight decline in price indices due to increased rainfall in southern regions [4]. - As of July 12, 2025, three out of five listed companies in the Chinese medicine industry reported positive net profit growth, with the lowest growth rate at 24.3% [5]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6451.72 points, up 1.08% last week, while the overall pharmaceutical index rose by 1.82% [2][17]. Valuation - The PE ratio (ttm) for the Chinese medicine sector is 27.86X, up 0.29X week-on-week, with a one-year maximum of 30.13X and a minimum of 22.58X. The PB ratio (lf) is 2.31X, up 0.03X, with a one-year maximum of 2.65X and a minimum of 1.99X [3][19]. Industry Trends - The Chinese medicine sector is entering the mid-year reporting season, with a focus on performance metrics such as inventory and accounts receivable [5]. - The report highlights three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, indicating potential growth areas within the sector [6][9]. Investment Recommendations - Recommended companies include those with strong R&D capabilities and unique products, as well as those less affected by price collection policies. Specific companies highlighted are Zhaoli Pharmaceutical, Pizaihuang, and Shouxiangu [10].

Policy Developments - The National Medical Products Administration (NMPA) is seeking public opinions on the revised procedures for conditional approval of drug listings to improve the review and approval system [2] Drug and Device Approvals - Xuno Pharmaceutical's oral cancer drug, Abexinostat, is proposed for priority review by the NMPA, aimed at adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [5] - LuKang Pharmaceutical has received the drug registration certificate for Gefitinib tablets, a first-generation targeted drug for non-small cell lung cancer with EGFR gene mutations [6] Capital Market Activities - Shenzhen Keximingde Medical Technology Co., Ltd. completed a multi-hundred million RMB A+ round financing, with funds allocated for brand building and R&D of soft endoscope products [8] - Buchang Pharmaceutical announced the abandonment of the preferential right to acquire shares in its subsidiary, Shaanxi Modern Innovation, resulting in an 86.50% ownership stake post-transfer [9] - Taiji Group plans to optimize its equity structure by acquiring stakes in its subsidiaries for a nominal price [10] Industry Developments - Chugai Pharmaceutical and Gero PTE have signed a $220 million collaboration agreement to integrate Gero's AI-driven platform into Chugai's R&D strategy for developing therapies for age-related diseases [12] - Kanghua Biotech has terminated its collaboration with Xiran Bochuang on the development of mRNA vaccines for tuberculosis, indicating a strategic shift towards in-house R&D capabilities [13] Shareholder Activities - Guizhou Jin Domain Medical Testing Group announced that major shareholder Guochuang Kaiyuan intends to reduce its stake by up to 1% through market transactions [16] - Haichuang Pharmaceutical reported that shareholder Yingchuang Power has cumulatively reduced its stake by 0.28% [17] - Tongrentang announced the resignation of its executive vice president, Zhang Chunyou, who will continue to serve in a managerial role at a subsidiary [18]

Core Points - The company held its 29th meeting of the 10th Board of Directors on July 7, 2025, where several key resolutions were passed, including the appointment of a new accounting firm and changes in board composition [1][2][3][4][5][6][7][8][9][10][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71] Group 1 - The company plans to change its accounting firm from Tianjian CPA to Lixin CPA for the 2025 financial report and internal control audit due to the expiration of the service term of the former firm [1][45][46] - The board approved the addition of a new director, Ms. Yu Xingyue, nominated by the controlling shareholder, with her term starting from the approval date by the shareholders' meeting [3][4][57][58] - The company intends to simplify its structure by canceling the indirect holding subsidiary, Hainan Taiji Pharmaceutical Import and Export Co., Ltd., to focus on its core business [5][62][63][64] Group 2 - The company will acquire 100% of the shares of Yuncheng Taiji Smart Traditional Chinese Medicine Co., Ltd. by purchasing the 90% and 10% stakes held by its subsidiaries for a nominal price of 1 yuan [6][31][32] - The company’s subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, will acquire 40% of Hainan Taiji Marine Pharmaceutical Co., Ltd. for 248,000 yuan, increasing its ownership from 60% to 100% [7][31][32] - The company has decided to cancel the supervisory board, transferring its responsibilities to the audit committee of the board, and will revise its articles of association accordingly [8][69][70]

Group 1 - The company held its 29th meeting of the 10th Board of Directors on July 7, 2025, with 11 out of 12 directors present, and the meeting was deemed legal and effective [1][2] - The company proposed to change its accounting firm from Tianjian Accounting Firm to Lixin Accounting Firm due to the expiration of the service term, which requires shareholder approval [1][2] - The company plans to supplement its board of directors by nominating Ms. Yu Xingyue, with her term starting from the approval date by the shareholders [2][6] Group 2 - The company intends to simplify its structure by liquidating its indirect subsidiary, Hainan Taiji Pharmaceutical Import and Export Co., Ltd., to focus on its core business [2][3] - The company will acquire 100% equity of Yuncheng Taiji Smart Traditional Chinese Medicine Co., Ltd. by purchasing shares from its subsidiaries for a nominal price of 1 yuan [3][4] - The company’s subsidiary, Chongqing Fuling Pharmaceutical Factory, will acquire 40% equity of Hainan Taiji Marine Pharmaceutical Co., Ltd. for 2.48 million yuan, increasing its ownership from 60% to 100% [4][5] Group 3 - The company approved the cancellation of the supervisory board and the revision of its articles of association, pending shareholder approval [5][6] - The company revised several governance documents, including the rules for shareholder meetings and board meetings, which will also be submitted for shareholder approval [5][6] - The company announced the convening of its second extraordinary general meeting of shareholders in 2025 [5][6]

Group 1 - The company, Chongqing Taiji Industrial (Group) Co., Ltd., is holding its second extraordinary general meeting of shareholders in 2025 on August 6, 2025, at 14:00 [1][4] - The meeting will take place at the company's conference room located at 1201, 18 Hengshan East Road, Yubei District, Chongqing [1][4] - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with voting available from 9:15 to 15:00 on the day of the meeting [1][4][5] Group 2 - The meeting will include non-cumulative voting proposals, and all A-share shareholders are eligible to vote [2][3] - The board of directors has approved the agenda for the meeting during its 29th meeting on July 9, 2025, and the details have been disclosed in various financial newspapers and the Shanghai Stock Exchange website [4][5] - There are no related shareholders that need to abstain from voting on the special resolution proposals [4] Group 3 - Shareholders must be registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, by the close of trading on July 29, 2025, to attend the meeting [5] - The company allows proxy representation for shareholders, and specific identification and authorization documents are required for attendance [5][6] - The company has provided an email contact for inquiries related to the meeting [6]

Core Points - The company, Chongqing Taiji Industry (Group) Co., Ltd., was established on December 28, 1993, and is a publicly listed company since November 18, 1997, on the Shanghai Stock Exchange [3][4][9] - The registered capital of the company is RMB 556.890744 million [3][9] - The company's business philosophy focuses on health and wellness, aiming to become a leading enterprise in traditional Chinese medicine with a strong emphasis on innovation and technology [6][14] Company Structure - The company is a permanent joint-stock company, with the chairman serving as the legal representative [4][5] - The company has established a Communist Party organization to conduct party activities within the company [6][14] - The company’s senior management includes the general manager, deputy general managers, board secretary, and financial director [5][6] Business Scope - The company’s business scope includes the production and retail of pharmaceuticals, health food production, and various medical device manufacturing [6][7] - The company is also involved in research and development in medicine and technology, as well as agricultural products [7][8] Share Structure - The company has issued a total of 556.890744 million shares, all of which are ordinary shares [9][10] - The company can increase its capital through various legal means, including public offerings and employee stock ownership plans [10][11] - The company is restricted from repurchasing its shares except under specific circumstances, such as capital reduction or mergers [10][11] Shareholder Rights - Shareholders have rights to dividends, voting, and the ability to request meetings and propose agenda items [16][17] - Shareholders holding more than 3% of shares for over 180 days can request to review the company's financial records [17][18] - The company must provide legal opinions on the validity of shareholder meetings and decisions [26][27] Governance - The company’s board of directors is responsible for major decisions, including profit distribution and capital changes [24][25] - The company must hold annual shareholder meetings within six months after the end of the fiscal year [26][27] - The company has established procedures for calling and conducting shareholder meetings, ensuring transparency and compliance with legal requirements [28][29]

Core Viewpoint - The document outlines the independent director working system of Chongqing Taiji Industry (Group) Co., Ltd., emphasizing the importance of independent directors in corporate governance and their role in protecting the interests of minority shareholders [1][2]. Summary by Sections General Principles - The system aims to standardize operations, enhance the role of independent directors, and improve corporate governance for high-quality development [1]. - Independent directors must not hold other positions within the company and should have no direct or indirect interests that could affect their independent judgment [2]. Qualifications and Appointment of Independent Directors - Independent directors must maintain independence and cannot be individuals with certain relationships or interests in the company [5]. - The board must have at least one accounting professional among the independent directors, and independent directors should not serve on more than three domestic companies [6][5]. Responsibilities and Duties of Independent Directors - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice to enhance decision-making [9]. - They have special rights, including hiring external consultants and proposing meetings [15]. Communication and Reporting - Independent directors must attend board meetings and can communicate with the board secretary to discuss agenda items [10]. - They are required to submit annual reports detailing their activities and interactions with minority shareholders [29]. Support and Compensation - The company must provide necessary working conditions and support for independent directors to fulfill their duties [31]. - Independent directors are entitled to compensation that reflects their responsibilities, and the company must cover expenses related to hiring professional services [36][19].

Core Points - The company has established an Audit Committee to enhance corporate governance and ensure compliance with relevant laws and regulations [1][2][3] - The Audit Committee is responsible for overseeing internal and external audit processes, ensuring accurate financial reporting, and maintaining effective internal controls [4][5][6] - The composition of the Audit Committee includes five members, with a majority being independent directors, and it is chaired by a professional accountant [3][4] - The committee's responsibilities include reviewing financial information, evaluating audit work, and supervising the internal audit department [9][10][11] - The company has also established a Remuneration and Assessment Committee to manage the evaluation and compensation of directors and senior management [13][14][15] - The Nomination Committee is responsible for selecting candidates for directors and senior management, ensuring a structured selection process [21][22][23] - The Strategic Committee focuses on long-term development strategies and major investment decisions, enhancing the company's core competitiveness [26][27][28]

重庆太极实业（集团）股份有限公司 董事会审计委员会实施细则 （2025 年 7 月修订） 第一章 总 则 第一条 为了推进重庆太极实业（集团）股份有限公司 （以下简称公司）提高公司治理水平,规范公司董事会审计 委员会的运作，根据《中华人民共和国公司法》（以下简称 《公司法》）、《中华人民共和国证券法》《上市公司治理准则 （2025 年修正）》《上市公司独立董事管理办法（2025 年修 正）》《上海证券交易所股票上市规则（2025 年 4 月修订）》 （以下简称《股票上市规则》）、《上海证券交易所上市公司 自律监管指引第 1 号——规范运作（2025 年 5 月修订）》等 相关法律、行政法规、部门规章、交易所业务规则以及《重 庆太极实业（集团）股份有限公司章程》（以下简称《公司 章程》）的要求，公司特设立董事会审计委员会，并制定本 实施细则。 第二条 审计委员会是董事会下设的专门委员会，对董 事会负责，向董事会报告工作，行使《公司法》规定的监事 会的职权，负责公司内、外部审计工作的监督、审核、沟通 及协调。 第三条 审计委员会成员须保证足够的时间和精力履 行委员会的工作职责，勤勉尽责，切实有效地监督公司的外 部 ...

重庆太极实业（集团）股份有限公司 章 程 二 0 二五年七月 - 1 - | 第一章 | 总则 | | --- | --- | | 第二章 | 经营宗旨和范围 - 5 - | | 第三章 | 股份 . | | 第四章 | 公司党委 - 10 - | | 第五章 | 股东和股东会 - 10 - | | 第六章 | 董事和董事会 . | | 第七章 | 高级管理人员 - 53 - | | 第八章 | 财务会计制度、利润分配和审计 - 56 - | | 第九章 | 通知和公告 | | 第十章 | 合并、分立、增资、减资、解散和清算 - 65 - | | | 第十一章 修改章程 | | | 第十二章 附则 | 第一章 总 则 第一条 为维护重庆太极实业（集团）股份有限公司（以 下简称公司）、股东、职工和债权人的合法权益，规范公司的组 织和行为，根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）和其他有关 规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股 份有限公司。 公司于 1993 年 12 月 28 日在涪陵市工商行政管理局注册登 记，取得营 ...